Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IWWM-12 2024 | The impact of clonal hematopoiesis on treatment strategies for Waldenström’s macroglobulinemia

Adam Sperling • 18 Oct 2024
IWWM-12 2024
Acute Myeloid Leukemia Leukemia Lymphoma Myelodysplastic Syndromes Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Bendamustine

Adam Sperling, MD, PhD, Dana Farber Cancer Institute, Boston, MA, discusses how the presence of clonal hematopoiesis might affect treatment strategies for patients with Waldenström’s macroglobulinemia. He emphasizes that current data is insufficient to warrant changes in therapy based on the presence of clonal hematopoiesis. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Adam Sperling

Detecting clonal hematopoiesis in patients with Waldenström's macroglobulinemia
1:08
Detecting clonal hematopoiesis in patients with Waldenström's macroglobulinemia
Adam Sperling • 18 Oct 2024
Clonal hematopoiesis increases the risk of progression in patients with asymptomatic WM
1:28
Clonal hematopoiesis increases the risk of progression in patients with asymptomatic WM
Adam Sperling • 18 Oct 2024
Mechanisms behind the loss of BCMA in multiple myeloma & options for patients
1:48
Mechanisms behind the loss of BCMA in multiple myeloma & options for patients
Adam Sperling • 27 Sep 2023
Clonal hematopoiesis in multiple myeloma and implications for therapy
1:58
Clonal hematopoiesis in multiple myeloma and implications for therapy
Adam Sperling • 27 Sep 2023

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals